MX371073B - Método para utilizar ciclodextrina. - Google Patents

Método para utilizar ciclodextrina.

Info

Publication number
MX371073B
MX371073B MX2014012200A MX2014012200A MX371073B MX 371073 B MX371073 B MX 371073B MX 2014012200 A MX2014012200 A MX 2014012200A MX 2014012200 A MX2014012200 A MX 2014012200A MX 371073 B MX371073 B MX 371073B
Authority
MX
Mexico
Prior art keywords
cellular
cyclodextrin
diabetes
cholesterol
relating
Prior art date
Application number
MX2014012200A
Other languages
English (en)
Spanish (es)
Other versions
MX2014012200A (es
Inventor
Fornoni Alessia
Merscher-Gomez Sandra
Original Assignee
L&F Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L&F Res Llc filed Critical L&F Res Llc
Publication of MX2014012200A publication Critical patent/MX2014012200A/es
Publication of MX371073B publication Critical patent/MX371073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014012200A 2012-04-13 2013-04-12 Método para utilizar ciclodextrina. MX371073B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Publications (2)

Publication Number Publication Date
MX2014012200A MX2014012200A (es) 2015-06-17
MX371073B true MX371073B (es) 2020-01-15

Family

ID=49328287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.

Country Status (8)

Country Link
US (4) US10195227B2 (enExample)
EP (2) EP4299121A3 (enExample)
JP (4) JP6491089B2 (enExample)
CN (2) CN111419870A (enExample)
CA (1) CA2870316C (enExample)
ES (1) ES2959119T3 (enExample)
MX (2) MX392972B (enExample)
WO (1) WO2013155485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2959119T3 (es) * 2012-04-13 2024-02-20 L&F Res Llc Método de uso de ciclodextrina
WO2014159659A1 (en) 2013-03-12 2014-10-02 Stein Emily A Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
WO2016201137A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
JP2019533011A (ja) * 2016-09-19 2019-11-14 アトン ポロス ライフサイエンシーズ シクロデキストリン系ポリマー、方法、組成物及びその応用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
KR20210084480A (ko) 2018-10-29 2021-07-07 싸이클로 테라퓨틱스, 아이엔씨. 알츠하이머 질환을 치료하는 방법
CA3125554A1 (en) 2019-01-03 2020-07-09 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
JP2023505387A (ja) * 2019-11-11 2023-02-08 厚雄 越智 体細胞をリプログラムするための方法およびキット
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US20240000826A1 (en) * 2020-08-27 2024-01-04 Beren Therapeutics P.B.C. Methods for the treatment of cardiovascular disease with cyclodextrins
JP2023543133A (ja) * 2020-08-27 2023-10-13 ベレン セラピューティクス ピー．ビー．シー． シクロデキストリンによるコレステロール結晶塞栓症の治療方法
KR20230096976A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 예방 방법
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
WO2022178318A1 (en) * 2021-02-18 2022-08-25 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
US20240238327A1 (en) * 2021-09-01 2024-07-18 Renatus Inc. Pharmaceutical composition comprising gamma-cyclodextrin polymer and uses thereof
AU2023220047A1 (en) 2022-02-18 2024-09-19 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
WO2000025803A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
CA2480668C (en) 2002-08-19 2009-11-24 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
JP2004323443A (ja) 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
US20080096967A1 (en) 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
US7670817B2 (en) 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EA200900571A1 (ru) 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
AU2009303300A1 (en) 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrones for the treatment of metabolic disorders
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
WO2010103823A1 (ja) 2009-03-12 2010-09-16 パナソニック株式会社 画像表示装置および画像表示方法
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
WO2011057172A1 (en) 2009-11-06 2011-05-12 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
WO2012012473A1 (en) * 2010-07-19 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
WO2012054321A2 (en) * 2010-10-19 2012-04-26 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
ES2959119T3 (es) * 2012-04-13 2024-02-20 L&F Res Llc Método de uso de ciclodextrina

Also Published As

Publication number Publication date
CN104244956B (zh) 2020-04-17
JP2021155436A (ja) 2021-10-07
US20210228616A1 (en) 2021-07-29
EP4299121A2 (en) 2024-01-03
CA2870316C (en) 2022-04-19
JP2018203747A (ja) 2018-12-27
EP2836221B1 (en) 2023-07-05
US10980828B2 (en) 2021-04-20
MX2020000205A (es) 2022-06-06
JP6491089B2 (ja) 2019-03-27
ES2959119T3 (es) 2024-02-20
MX2014012200A (es) 2015-06-17
MX392972B (es) 2025-03-21
CA2870316A1 (en) 2013-10-17
EP2836221A4 (en) 2016-07-27
CN104244956A (zh) 2014-12-24
US20230338412A1 (en) 2023-10-26
EP2836221A2 (en) 2015-02-18
WO2013155485A2 (en) 2013-10-17
US20150065457A1 (en) 2015-03-05
US10195227B2 (en) 2019-02-05
US20190262385A1 (en) 2019-08-29
JP2015512949A (ja) 2015-04-30
CN111419870A (zh) 2020-07-17
WO2013155485A3 (en) 2013-12-19
EP4299121A3 (en) 2024-07-24
JP2023178518A (ja) 2023-12-15

Similar Documents

Publication Publication Date Title
MX2020000205A (es) Metodo para utilizar ciclodextrina.
MX346428B (es) Metodo para tratar eccema.
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
WO2013003601A9 (en) Method for treating phytophotodermatitis
EA201491386A1 (ru) Соединения, ингибирующие металлоферменты
WO2013056148A3 (en) Scd1 antagonists for treating cancer
AU2014230129A8 (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP2542584B8 (en) Methods for treating pancreatic cancer
EP2672967A4 (en) COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATING THEREFOR
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
WO2012149472A9 (en) Methods, compositions, and kits for treating and preventing neurological conditions
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
WO2012177925A8 (en) Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
MX371378B (es) Moduladores mejoradores de la actividad de hec1 y metodos para los mismos.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MY164954A (en) Method for purifying organic diphosphite compounds
BR112015013152A2 (pt) composição para tratamento de uma formação subterrânea , método para tratar uma formação subterrânea , e método para reduzir a viscosidade de óleo cru.
WO2012134626A3 (en) Processes for enzymatic refining of pretreated cellulosic material for saccharification
MX2015007778A (es) Prediccion de bioactivacion molecular.
WO2011083483A3 (en) Method for treatment of inflammatory disease and disorder
WO2012170720A3 (en) Methods and compositions for treating brain cancer
WO2012054782A3 (en) Fluoroalkoxylation of organic compounds
MX343856B (es) Procedimiento para la preparación de derivados 1-h-pirrolidin-2,4-diona.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: L&F RESEARCH LLC

FG Grant or registration